Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study.
Overview
- Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan
- School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan
- Department of Anesthesiology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan
- Department of Anesthesiology, Chi Mei Hospital, Liouying, Tainan, Taiwan
Abstract
Purpose: SGLT2 inhibitors have been associated with reduced dementia risk in patients with type 2 diabetes mellitus (T2DM); however, whether this association extends to patients with traumatic brain injury (TBI) remains unknown.
Patients and Methods: We conducted a new-user, active-comparator, retrospective cohort study using the TriNetX Research Network. Adults aged ≥50 years with T2DM and a history of TBI who newly initiated an SGLT2 inhibitor were compared with new users of a DPP-4 inhibitor as the active-comparator group between 2014 and 2023. A 1-year landmark period was applied before the outcome was ascertained. The primary outcome was incident dementia during an analytic window extending from day 365 to up to 10 years after the index date. Secondary outcomes included dementia subtypes (ie, vascular dementia or Alzheimer’s disease) and all-cause mortality. Propensity score matching, sensitivity analyses, and multivariable Cox regression were performed.
Results: After matching, 3,877 patients were included in each group. Incident dementia occurred in 129 patients (3.33%) in the SGLT2 inhibitor group and 243 patients (6.27%) in the DPP-4 inhibitor group (HR, 0.71; 95% CI, 0.57–0.88; p = 0.002). In exploratory secondary analyses, associations were observed for vascular dementia (HR, 0.49; p = 0.005) and all-cause mortality (HR, 0.76; p < 0.001), but not for Alzheimer’s disease (HR, 0.90; p = 0.654). A similar exploratory association was observed in the code-defined non-concussion intracranial injury subgroup (HR, 0.65; p = 0.004).
Conclusion: In this retrospective cohort study, SGLT2 inhibitor use was associated with a lower risk of incident dementia in patients with T2DM and TBI. These hypothesis-generating findings warrant further prospective validation.
Reproduced under the paper's license (CC BY-NC), from the paper cited above.
Code
No file of the authors' code could be read here: it is described below, and read at its source.
dovepress.com/article/supplementary_file
Availability: 1 check, the latest on 27 September 2026: the link answers (HTTP 200)
- 27 September 2026: the link answers (HTTP 200)
Tracing map
Proposed by the machine: these links were found in the paper and verified at the source, without human review. The map will receive a Zenodo DOI once one of the paper's authors has validated it with their ORCID.
What the map holds:
- 1 repository of the authors' code, each at its verified commit, with its license and how the link was found in the paper;
- 0 scripts, each with its path and the digest of its content;
- no match between paragraphs and code yet;
- neither the text of the paper nor the code itself.
Its JSON (tracing-map.json) is deposited on Zenodo with its DOI once the map is validated.
Data
No dataset and no data link were found in the paper.
Data Sharing Statement
The data utilized in this study were obtained from the TriNetX Research Network under a collaborative agreement and are not publicly available. De-identified data may be made available upon reasonable request to the corresponding author, pending approval from TriNetX and compliance with the required data-sharing agreement or network membership.
Reproduced under the paper's license (CC BY-NC), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, pages, dates, 3 authors, 5 keywords, 13 MeSH terms, 1 funder, 36 references.
Cite
This paper
Hung, K.-C., Weng, H.-L., & Chen, I.-W. (2026). Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study. Drug design, development and therapy, 20, 624727. https://
BibTeX
@article{hung2026lower,
author = {Hung, Kuo-Chuan and Weng, Hsiu-Lan and Chen, I-Wen},
title = {{Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study}},
journal = {Drug design, development and therapy},
year = {2026},
month = aug,
volume = {20},
pages = {624727},
publisher = {Dove Press},
issn = {1177-8881},
doi = {10.2147/
url = {https://
pmid = {42609986},
pmcid = {PMC13479792}
}
RIS
TY - JOUR
AU - Hung, Kuo-Chuan
AU - Weng, Hsiu-Lan
AU - Chen, I-Wen
TI - Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study
T2 - Drug design, development and therapy
J2 - Drug Des Devel Ther
PY - 2026
DA - 2026/
VL - 20
SP - 624727
SN - 1177-8881
PB - Dove Press
DO - 10.2147/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.2147/
"type": "article-journal",
"title": "Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study",
"container-title": "Drug design, development and therapy",
"author": [
{
"family": "Hung",
"given": "Kuo-Chuan"
},
{
"family": "Weng",
"given": "Hsiu-Lan"
},
{
"family": "Chen",
"given": "I-Wen"
}
],
"container-title-short":
"volume": "20",
"page": "624727",
"DOI": "10.2147/
"PMID": "42609986",
"PMCID": "PMC13479792",
"ISSN": "1177-8881",
"publisher": "Dove Press",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
8,
11
]
]
}
}
The tracing map gets a citation of its own once an author has validated it and it has a DOI.
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1093/braincomms/fcaf009 [code]
- Amyloid-β and tau deposition in traumatic brain injury: a study of Vietnam War veterans.Journal: Brain communicationsIn common: traumatic brain injury, Alzheimer's / dementia, 2 references
- [2] doi:10.1089/neur.2025.0052
- Identifying a Biological Signature of Trauma-Related Neurodegeneration Following Repeated Traumatic Brain Injuries Compared with Healthy Controls.Journal: Neurotrauma reportsIn common: traumatic brain injury, other, Alzheimer's / dementia, 2 other categories, 1 reference
- [3] doi:10.1093/braincomms/fcag055 [code]
- Serum biomarker trajectory clusters predict functional outcome and quality of life for traumatic brain injury.Journal: Brain communicationsIn common: traumatic brain injury, other, clinical / translational, 1 reference
- [4] doi:10.1093/braincomms/fcaf216 [code]
- Distinct clinical phenotypes and their neuroanatomic correlates in chronic traumatic brain injury.Journal: Brain communicationsIn common: traumatic brain injury, clinical / translational, 1 reference
- [5] doi:10.1038/s41598-026-53148-5
- Neurovascular and inflammatory effects of biperiden in the acute phase of moderate traumatic brain injury: evidence from a non-human primate model.Journal: Scientific reportsIn common: traumatic brain injury, other, 1 reference
- [6] doi:10.1186/s40478-026-02240-y
- GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome.Journal: Acta neuropathologica communicationsIn common: traumatic brain injury, other, 1 reference
- [7] doi:10.1126/sciadv.aed8653
- Targeting astrocytic Dp71 attenuates BBB disruption after traumatic brain injury through WTAP-associated m&
lt;sup& gt;6& lt;/ sup& gt;A regulation of MMP2. Journal: Science advancesIn common: traumatic brain injury, 1 reference - [8] doi:10.1002/alz.71471 [code]
- How does type 2 diabetes modify the risk of Alzheimer's disease?Journal: Alzheimer's & dementia : the journal of the Alzheimer's AssociationIn common: Alzheimer's / dementia, other condition, 1 reference
- [9] doi:10.1371/journal.pone.0345651 [code]
- Non-concussive head impacts sustained during American football correlate with changes in gut microbiome diversity and composition.Journal: PloS oneIn common: traumatic brain injury, clinical / translational, 1 reference
- [10] doi:10.1371/journal.pone.0320004
- Aerobic exercise and brain structure among military service members and Veterans with varying histories of mild traumatic brain injury: A LIMBIC-CENC exploratory investigation.Journal: PloS oneIn common: traumatic brain injury, clinical / translational, 1 reference
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Validate its tracing map
You validate the map as this page shows it: 1 repository of the authors' code, each at its verified commit and with its license, 0 scripts, and 0 matches between paragraphs and code (see the Code and Map sections). It then receives a DOI on Zenodo, with you (your ORCID iD) and OSCR as its creators; the code itself is not deposited.
The map's fingerprint: sha256:fe927c54c4af0c51…
Add the badge to the code's README
If you are an author or a maintainer of this paper's code, you can add this badge. It says what OSCR knows of the paper (its code, its validated tracing map) and links the code to this page. Paste one of these snippets under the README's title. Keep the two marks around it, so that the badge can be replaced in place and is never added twice. OSCR changes nothing in your repository.
Markdown
<!-- oscr-badge:start -->
[](https://openscicode.org/badge/doi/10.2147/dddt.s624727)
<!-- oscr-badge:end -->reStructuredText
.. oscr-badge:start
.. image:: https://openscicode.org/badge/doi/10.2147/dddt.s624727.svg
:target: https://openscicode.org/badge/doi/10.2147/dddt.s624727
:alt: OSCR
.. oscr-badge:endHTML
<!-- oscr-badge:start -->
<a href="https://openscicode.org/badge/doi/10.2147/dddt.s624727"><img src="https://openscicode.org/badge/doi/10.2147/dddt.s624727.svg" alt="OSCR"></a>
<!-- oscr-badge:end -->If you choose to, you can have the badge kept up to date for you, with oscr badge --write from the command line or with the GitHub Action in your repository's workflows. Every other form and option (a card, AsciiDoc, LaTeX, shields.io) is on the badge page.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Report a mismatch between the code and the paper · Report a code error (signed in)
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Report a reproduction failure (signed in)
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
